Pathological, clinical and prognostic characteristics of breast cancer in Central Sudan versus Northern Italy: Implications for breast cancer in Africa

Histopathology

Volumn 52, Issue 4, 2008, Pages 445-456

  Awadelkarim, K D ^a,b,c,d   Arizzi, C ^b   Elamin, E O M ^e   Hamad, H M A ^e   De Blasio, P ^f   Mekki, S O ^g   Osman, I ^e   Biunno, I ^d   Elwali, N E ^a   Mariani Costantini, R ^c   Barberis, M C ^b,h  

^a UNIVERSITY OF GEZIRA   (Sudan)

^b IRCCS MULTIMEDICA   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

^d INSTITUTE OF BIOMEDICAL TECHNOLOGIES   (Italy)

^e Radiation and Isotope Centre Khartoum (RICK)   (Sudan)

^f Integrated Systems Engineering   (Italy)

^g FEDERAL MINISTRY OF HEALTH   (Sudan)

^h OSPEDALI RIUNITI   (Italy)

Author keywords

Africa; Breast cancer; ER; Ethnicity; Her 2 neu; Immunohistochemistry; Italy; PR; Subtype; Sudan

Indexed keywords

ANTIGEN; CYTOKERATIN 17; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FORMALDEHYDE; PARAFFIN; PROGESTERONE RECEPTOR;

ADULT; AFRICA; AGE DISTRIBUTION; AGED; ANTIGEN RETRIEVAL; ARTICLE; BREAST CANCER; CANCER PREVENTION; CANCER STAGING; CANCER THERAPY; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; ETHNICITY; EUROPE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ITALY; LYMPH NODE METASTASIS; PATHOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; SUDAN;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; ITALY; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SUDAN; TUMOR MARKERS, BIOLOGICAL;

EID: 40149108024     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2008.02966.x     Document Type: Article

References (65)

1. Gondos A, Brenner H, Wabinga H, Parkin DM. Cancer survival in Kampala, Uganda. Br. J. Cancer 2005 92 1808 1812.
2. Ikpatt OF, Kuopio T, Ndoma-Egba R, Collan Y. Breast cancer in Nigeria and Finland: epidemiological, clinical and histological comparison. Anticancer Res. 2002 22 3005 3012.
3. Morris K. Cancer? In Africa? Lancet Oncol. 2003 4 5.
4. Kerr F, Kerr D. Do we bear any moral responsibility for improving cancer care in Africa? Ann. Oncol. 2006 17 1730 1731.
5. Ekortarl A, Ndom P, Sacks A. A study of patients who appear with far advanced cancer at Yaounde General Hospital, Cameroon, Africa. Psychooncology 2007 16 255 257.
6. Nyagol J, Nyong'o A, Byakika B et al. Routine assessment of hormonal receptor and her-2/neu status underscores the need for more therapeutic targets in Kenyan women with breast cancer. Anal. Quant. Cytol. Histol. 2006 28 97 103.
7. Oluwatosin OA. Rural women's perception of breast cancer and its early-detection measures in Ibadan, Nigeria. Cancer Nurs. 2006 29 461 466.
8. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005 55 74 108.
9. Amir H, Kwesigabo G, Aziz MR, Kitinya JN. Breast cancer and conservative surgery in sub Saharan Africa. East Afr. Med. J. 1996 73 83 87.
10. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. Lyon : IARC Press, 2004.
11. Gondos A, Chokunonga E, Brenner H et al. Cancer survival in a southern African urban population. Int. J. Cancer 2004 112 860 864.
12. Adesunkanmi AR, Lawal OO, Adelusola KA, Durosimi MA. The severity, outcome and challenges of breast cancer in Nigeria. Breast 2006 15 399 409.
13. Fregene A, Newman LA. Breast cancer in sub-Saharan Africa: how does it relate to breast cancer in African-American women? Cancer 2005 103 1540 1550.
14. Ijaduola TG, Smith EB. Pattern of breast cancer among white-American, African-American, and nonimmigrant west-African women. J. Natl Med. Assoc. 1998 90 547 551.
15. Okobia MN, Bunker CH. Epidemiological risk factors for breast cancer - a review. Niger. J. Clin. Pract. 2005 8 35 42.
16. Okobia M, Bunker C, Zmuda J et al. Case-control study of risk factors for breast cancer in Nigerian women. Int. J. Cancer 2006 119 2179 2185.
17. Mbonde MP, Amir H, Mbembati NA, Holland R, Schwartz-Albiez R, Kitinya JN. Characterisation of benign lesions and carcinomas of the female breast in a sub-Saharan African population. Pathol. Res. Pract. 1998 194 623 629.
18. Chu KC, Anderson WF. Rates for breast cancer characteristics by estrogen and progesterone receptor status in the major racial/ethnic groups. Breast Cancer Res. Treat. 2002 74 199 211.
19. Carey LA, Perou CM, Livasy CA et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. J. Am. Med. Assoc. 2006 295 2492 2502.
20. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000 406 747 752.
21. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 2001 98 10869 10874.
22. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 2003 100 8418 8423.
23. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991 19 403 410.
24. Greene FL, Page DL, Fleming ID et al. (eds). AJCC cancer staging manual, 6th edn. New York, NY, USA : Springer-Verlag, 2002.
25. WHO. International histological classification of tumours. Histologic types of breast tumours. Geneva : WHO, 1991.
26. Anderson WF, Chen BE, Jatoi I, Rosenberg PS. Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer. Breast Cancer Res. Treat. 2006 100 121 126.
27. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J. Clin. Oncol. 2003 21 1973 1979.
28. Arpino G, Green SJ, Allred DC et al. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin. Cancer Res. 2004 10 5670 5676.
29. Dowsett M, Houghton J, Iden C et al. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according to oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann. Oncol. 2006 17 818 826.
30. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann. Oncol. 2007 18 977 984.
31. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 2005 353 1673 1684.
32. Coudert BP, Arnould L, Moreau L et al. Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial. Ann. Oncol. 2006 17 409 414.
33. Gukas ID, Jennings BA, Mandong BM et al. Clinicopathological features and molecular markers of breast cancer in Jos, Nigeria. West Afr. J. Med. 2005 24 209 213.
34. Ikpatt OF, Ndoma-Egba R. Oestrogen and progesterone receptors in Nigerian breast cancer: relationship to tumour histopathology and survival of patients. Cent. Afr. J. Med. 2003 49 122 126.
35. Mbonde MP, Amir H, Schwartz-Albiez R, Akslen LA, Kitinya JN. Expression of estrogen and progesterone receptors in carcinomas of the female breast in Tanzania. Oncol. Rep. 2000 7 277 283.
36. Mbonde MP, Amir H, Akslen LA, Kitinya JN. Expression of oestrogen and progesterone receptors, Ki-67, p53 and BCL-2 proteins, cathepsin D, urokinase plasminogen activator and urokinase plasminogen activator-receptors in carcinomas of the female breast in an African population. East Afr. Med. J. 2001 78 360 365.
37. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007 109 25 32.
38. Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 2004 10 5367 5374.
39. van't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002 415 530 536.
40. Sudan Demographic and Health Survey 1989/1990. Sudan Demographic and Health Survey (SDHS). Khartoum, Sudan : Department of Statistics, Ministry of Economic and National Planning Khartoum, Sudan and Columbia, MD : Institute for Resource Development/Macro International, Inc., 1991.
41. El Moghraby AI. State of the environment in the Sudan. In McCabe M, Sadler B eds. UNEP studies of EIA practice in developing countrie. Geneva : UNEP, 2003 27 36.
42. FAO. Sudan Nutrition Profile - Food and Nutrition Division. 2005. Available at: ftp://ftp.fao.org/es/esn/nutrition/ncp/sdn.pdf accessed on 25 May 2007.
43. Awadelkarim KD, Aceto G, Veschi S et al. BRCA1 and BRCA2 status in a Central Sudanese series of breast cancer patients: interactions with genetic, ethnic and reproductive factors. Breast Cancer Res. Treat. 2007 102 189 199.
44. Institute of Nuclear Medicine Molecular Biology & Oncology (INMO). INMO Annual Report. Wad Medani : Unit of Statistics, 2006.
45. Birner P, Oberhuber G, Stani J et al. Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin. Cancer Res. 2001 7 1669 1675.
46. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 2007 25 118 145.
47. Fulford LG, Reis-Filho JS, Ryder K et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res. 2007 9 R4.
48. Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales AR. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am. J. Clin. Pathol. 2005 123 21 27.
49. Rhodes A, Jasani B, Balaton AJ et al. Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in Europe. Documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a major contributory element of unreliable assays. Am. J. Clin. Pathol. 2001 115 44 58.
50. Goldstein NS, Ferkowicz M, Odish E, Mani A, Hastah F. Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am. J. Clin. Pathol. 2003 120 86 92.
51. Menard S, Casalini P, Tomasic G et al. Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviors. Breast Cancer Res. Treat. 1999 55 169 177.
52. Al-Kuraya K, Schraml P, Sheikh S et al. Predominance of high-grade pathway in breast cancer development of Middle East women. Mod. Pathol. 2005 18 891 897.
53. Katz A, Saad ED, Porter P, Pusztai L. Primary systemic chemotherapy of invasive lobular carcinoma of the breast. Lancet Oncol. 2007 8 55 62.
54. Marcus JN, Watson P, Page DL, Lynch HT. Pathology and heredity of breast cancer in younger women. J. Natl Cancer Inst. Monogr. 1994 16 23 34.
55. Middleton LP, Chen V, Perkins GH, Pinn V, Page D. Histopathology of breast cancer among African-American women. Cancer 2003 97 (Suppl. 1 253 257.
56. Pegoraro RJ, Karnan V, Nirmul D, Joubert SM. Estrogen and progesterone receptors in breast cancer among women of different racial groups. Cancer Res. 1986 46 2117 2120.
57. Ursin G, Bernstein L, Lord SJ et al. Reproductive factors and subtypes of breast cancer defined by hormone receptor and histology. Br. J. Cancer 2005 93 364 371.
58. Eltigani EE. Childbearing in five Arab countries. Stud. Fam. Plann. 2001 32 17 24.
59. Pichon MF, Milgrom E. Oestrogen receptor negative-progesterone receptor positive phenotype in 1,211 breast tumours. Br. J. Cancer 1992 65 895 897.
60. McGuire WL, Chamness GC, Fuqua SA. Estrogen receptor variants in clinical breast cancer. Mol. Endocrinol. 1991 5 1571 1577.
61. Dowsett M. Estrogen receptor: methodology matters. J. Clin. Oncol. 2006 24 5626 5628.
62. Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J. Clin. Oncol. 2005 23 7350 7360.
63. Marcom PK, Isaacs C, Harris L et al. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res. Treat. 2007 102 43 49.
64. Foulkes WD, Stefansson IM, Chappuis PO et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J. Natl Cancer Inst. 2003 95 1482 1485.
65. Adebamowo CA, Famooto A, Ogundiran TO, Aniagwu T, Nkwodimmah C, Akang EE. Immunohistochemical and molecular subtypes of breast cancer in Nigeria. Breast Cancer Res. Treat. 2007. Available at: http://www.springerlink.com/content/ 91071730825638x4 accessed on 5 August 2007.